News
AstraZeneca Launches At-Home FluMist
Digest more
AstraZeneca PLC closed 12.32% short of its 52-week high of £133.88, which the company achieved on September 3rd.
The treatment is one for those suffering with lung cancer who never smoked, a group of patients who account for up to 25% of those who develop the disease due to an oncogenic driver mutation. Tagrisso ...
Stocktwits on MSN8h
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca
FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...
AstraZeneca (LSE:AZN) recently launched "FluMist Home," an at-home flu vaccine delivery service, marking an important ...
AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...
Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for ...
FluMist has been approved since 2003, but—until last year—only for administration by a healthcare practitioner. The new nod ...
He said about Britain that the firm needed “to see that there is access and a reason to invest.” This is partly a negotiating tactic to get a better deal from the British government, including on what ...
While the numbers may seem high, they are still far below the pay of top executives in the United States, the study has found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback